Retatrutide

Clinical Trials

Retatrutide (LY3437943)

Aliases
LY3437943, Triple-G
Administration
Subcutaneous injection (once weekly)

How it works

  1. Dual GIP and GLP-1 receptor agonism (shared with tirzepatide)

    It copies two gut hormones at once, the same combination tirzepatide uses.

  2. Additional glucagon receptor agonism, increasing energy expenditure

    It also activates a third hormone pathway that raises how many calories your body burns at rest — a mechanism no other approved obesity drug currently has.

  3. Hypothalamic appetite suppression

    It acts on the brain's hunger center to reduce appetite.

  4. Improves insulin sensitivity and beta-cell function

    It helps your body's cells respond better to insulin.

Result

The most substantial weight loss demonstrated by any injectable drug studied so far, driven by three separate hormone pathways acting together. Trial participants reported dramatic, visible weight loss along with sharply reduced hunger and food cravings.